The purpose of this review is to review recent literature with regard to patient satisfaction with overactive bladder treatments. The latest research looks into beta-3 agonist, Mirabegron, to treat OAB and sacral and pudendal neuromodulation for severe OAB. Conservative management effectively alleviated OAB symptoms without the adverse effects of antimuscarinic medications. PFME appears to be the most successful treatment. Medical management continues to show efficacy but with very bothersome side effects in a substantial proportion of patients and with significant cost, leading to medical noncompliance and discontinuation of therapy. BTX-A injections and neuromodulation also are quite efficacious as a third-line treatment option for refractory OAB patients or patients who are no longer candidates for second-line therapy.